Exploration of Digestive Diseases

Factors	Descriptions
Factors associated with a higher likelihood of HBsAg seroclearance	Low quantitative HBsAg [10–12, 19], e.g., < 100 IU/mL for Asians and < 1,000 IU/mL for Caucasians [12, 30]
Strong kinetic of HBsAg level decline [11, 13]
Low HBV DNA level, e.g., HBV DNA level < 2,000 IU/mL in untreated patients [12]; pretreatment HBV DNA level < 20,000 IU/mL [17]; HBV DNA level < 100 IU/mL at week 24 after antiviral treatment cessation [18]
Negative HBeAg [10, 16]
Older age [11, 12, 16]
Non-Asian population [11, 19, 30]
HCV co-infection [21]
Novel HBV treatments such as siRNA and ASO [31]
Interferon treatment [10]
Factors that may be associated with HBsAg seroclearance	HBV genotype A or D [16, 19]
Presence of hepatic steatosis [12, 29]
HIV co-infection [23–25]

Factors

Descriptions

Factors associated with a higher likelihood of HBsAg seroclearance

Low quantitative HBsAg [10–12, 19], e.g., < 100 IU/mL for Asians and < 1,000 IU/mL for Caucasians [12, 30]

Strong kinetic of HBsAg level decline [11, 13]

Low HBV DNA level, e.g., HBV DNA level < 2,000 IU/mL in untreated patients [12]; pretreatment HBV DNA level < 20,000 IU/mL [17]; HBV DNA level < 100 IU/mL at week 24 after antiviral treatment cessation [18]

Negative HBeAg [10, 16]

Older age [11, 12, 16]

Non-Asian population [11, 19, 30]

HCV co-infection [21]

Novel HBV treatments such as siRNA and ASO [31]

Interferon treatment [10]

Factors that may be associated with HBsAg seroclearance

HBV genotype A or D [16, 19]

Presence of hepatic steatosis [12, 29]

HIV co-infection [23–25]